TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15571956
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily for three months followed by 1 mg daily for five years
Study: 11256555
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (270 microg four times daily) for 2 weeks
Study: 11256555
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 2 weeks of inhaled albuterol
Study: 9143863
Drug: Colchicine (1.0‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.0‐2.0 mg.day‐1) for 2‐13 years
Study: 9143863
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine (2 mg) infusion
Study: 26741384
Drug: Juvéderm Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvéderm Ultra (24 mg/mL)
Study: 26741384
Drug: Restylane (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane (20 mg/mL)
Study: 25335781
Drug: Anthocyanin intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin intake (271 mg and 7.11 mg C3g eq) in S2 trial
Study: 25335781
Drug: Anthocyanin intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin intake (346 mg C3g eq) in L1 trial
Study: 10965103
Drug: Cefpirome (CPM)
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (CPM) 2 g i.v. every 12 h
Study: 10965103
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g i.v. every 8 h
Study: 8648203
Drug: Schwarz (SW9)
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz (SW9) strain of measles vaccine
Study: 8648203
Drug: Schwarz (SW6)
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz (SW6) strain of measles vaccine
Study: 8648203
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) strain of measles vaccine
Study: 6308068
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (20 mg b.i.d.)
Study: 6308068
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg b.i.d.)
Study: 6308068
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (20 mg b.i.d.) and Hydrochlorothiazide (25 mg b.i.d.) in combination
Study: 30287097
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Solution
Study: 15133294
Drug: Radon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radon therapy
Study: 12575588
Drug: TWP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: TWP combined with MT (TWP 10 mg orally, 3 times a day; MT 7.5 mg orally once a week)
Study: 12575588
Drug: MT (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT (15 mg orally, once every week)
Study: 9782544
Drug: Anti-gravity suit
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-gravity suit (anti-G)
Study: 30554600
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream twice daily
Study: 30554600
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream once daily
Study: 30554600
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream
Study: 26628383
Drug: Warfarin (n=814)
Normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (n=814)
Study: 23160920
Drug: Olmesartan medoxomil/amlodipine
Normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (single dose)
Study: 23160920
Drug: Olmesartan medoxomil/amlodipine
Normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (multiple doses)
Study: 23160920
Drug: Olmesartan medoxomil/amlodipine
Normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (both single and multiple doses)
Study: 15776832
Drug: terazosine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: terazosine (5 mg/day, n = 29)
Study: 10512904
Drug: Aptiganel HCl
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel HCl (4.5 mg bolus followed by 0.75 mg/h infusion for 12 hours)
Study: 10512904
Drug: Aptiganel HCl
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel HCl (6 mg bolus followed by 1 mg/h infusion)
Study: 10512904
Drug: Aptiganel HCl
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel HCl (7.5 mg bolus)
Study: 10512904
Drug: Aptiganel HCl
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel HCl (3 mg, 4.5 mg, 6 mg, 7.5 mg bolus doses)
Study: 7860749
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg draflazine
Study: 7860749
Drug: Adenosine dosages
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine dosages (0.15, 0.5, 1.5, 5, 15, and 50 micrograms/100 ml forearm per min)
Study: 1781051
Drug: Gitadyl (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gitadyl (a herbal medicine containing 110 mg fever few, 90 mg American aspen, and 60 mg milfoil)
Study: 1781051
Drug: Ibuprofen (Ibumetin)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Ibumetin) 1,200 mg
Study: 31825471
Drug: Sacubitril/valsartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (titrated to 97/103 mg twice daily)
Study: 31825471
Drug: Enalapril (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (titrated to target dose, 10 mg twice daily)
Study: 27151378
Drug: Low-dose CD34+
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CD34+ stem cells (1×10^5 CD34/kg body weight)
Study: 27151378
Drug: High-dose CD34+
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CD34+ stem cells (5×10^5 CD34/kg)
Study: 27151378
Drug: Low-dose CD34+
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CD34+ stem cells
Study: 27151378
Drug: High-dose CD34+
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CD34+ stem cells
Study: 19512866
Drug: Nefopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (100 ng/ml) and Clonidine (2.5 microg/kg)
Study: 19512866
Drug: Nefopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (100 ng/ml) and Alfentanil (150 ng/ml)
Study: 12324985
Drug: New patterns
Approvals — FDA: no, EMA: no, PMDA: no
Description: New patterns of insulin use
Study: 29178731
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush with tapered bristles (Oral‐B Super Thin Indicator toothbrush, OM159)
Study: 29178731
Drug: Marketed control
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed control toothbrush (Study 1: Oral‐B Complete Clean & Sensitive toothbrush; Study 2: Crest Pro‐Health Complete 7 Brush 35 toothbrush)
Study: 23714676
Drug: Sham infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham infusions (n = 18)
Study: 16998290
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg i.v. initially and 1 mg i.v. every 4 hours for 3 days)
Study: 16998290
Drug: Octreotide (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (continuous infusion of 25 microgram/h for 5 days)
Study: 11074150
Drug: Nasal nicotine
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal nicotine spray (1-2mg)
Study: 11074150
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo spray of oleoresin of pepper
Study: 8513038
Drug: Fenfluramine (FF)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (FF) 60 mg orally
Study: 26860800
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng (3.0 g/day)
Study: 23156978
Drug: Nebulized terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbinafine solution made with crushed tablet
Study: 23156978
Drug: Nebulized terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbinafine solution made with raw drug powder
Study: 19029416
Drug: Structured QOL
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured QOL diary (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and the related lung cancer module LC13) completed weekly for 16 weeks
Study: 17545356
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone dosage of 0.11 IU/kg body weight per day
Study: 17545356
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone dosage of 0.21 IU/kg body weight per day
Study: 11000734
Drug: ALM subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALM subgroup (lansoprazole + amoxicillin + metronidazole)
Study: 11000734
Drug: ALC subgroup
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALC subgroup (lansoprazole + amoxicillin + clarithromycin)
Study: 8834030
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg/day) and ursodeoxycholic acid
Study: 1468087
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride solution
Study: 1468087
Drug: Slow-release magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release magnesium chloride tablets
Study: 1468087
Drug: Magnesium gluconate
Normalized name: Magnesium Gluconate
DrugBank: Magnesium gluconate (DB13749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium gluconate tablets
Study: 28919843
Drug: Phenylalanine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine (3 g/dose)
Study: 12675760
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 1:1000 nebulized adrenaline
Study: 12675760
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of nebulized normal saline
Study: 9186254
Drug: Antiepileptic polytherapy
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic polytherapy
Study: 27276401
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) at 600-1800 mg
Study: 25876343
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment (acupoint injection + neural electrical stimulation)
Study: 30957447
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection
Study: 20458350
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day for 4 months)
Study: 20458350
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day for 2 months after crossover)
Study: 16077385
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg . kg ‐1) during induction of anesthesia
Study: 12663440
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg/kg/day continuous intravenous infusion) in combination with induction chemotherapy (idarubicine and cytarabine)
Study: 12663440
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (idarubicine and cytarabine) with or without quinine
Study: 31361094
Drug: deoxyribonucleate sodium
Normalized name: deoxyribonucleases
Approvals — FDA: no, EMA: no, PMDA: no
Description: deoxyribonucleate sodium (75 mg via intramuscular injection every 48 hours for 1 month)
Study: 31361094
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy without deoxyribonucleate sodium)
Study: 27964837
Drug: Sitagliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin plus basal insulin (glargine once daily)
Study: 27964837
Drug: Basal-bolus regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus regimen (glargine once daily and rapid-acting insulin before meals)
Study: 25942458
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg two times a day for 7 days
Study: 25942458
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg once a day for 7 days
Study: 25942458
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin 20 mg once a day + raltegravir 400 mg two times a day for 7 days
Study: 17352026
Drug: Low-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose regimen (group A): omeprazole 20 mg b.i.d, clarithromycin 250 mg b.i.d, amoxicillin 500 mg b.i.d
Study: 17352026
Drug: High-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose regimen (group B): omeprazole 20 mg b.i.d, clarithromycin 500 mg b.i.d, amoxicillin 1000 mg b.i.d
Study: 15449576
Drug: Special nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special nutritional formula providing 480 kcal, 31 g proteins, 120 IU vitamin E, 3.8 microg vitamin B12, 400 microg folic acid, 10(9) cfu Lactobacillus paracasei (NCC 2461), and 6 g of fructo‐oligosaccharides
Study: 11678298
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone acetate injection with local anesthetic (group A)
Study: 11678298
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy measures plus nonsteroidal anti‐inflammatory drugs (group B)
Study: 9395778
Drug: Physostigmine salicylate,
Normalized name: Physostigmine Salicylate, 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate, 8 mg/ml, one drop instilled at 7 AM and repeated on alternate hours throughout the day
Study: 9395778
Drug: Physostigmine salicylate,
Normalized name: Physostigmine Salicylate, 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate, 8 mg/ml
Study: 7734028
Drug: Levosulpiride (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (75 mg/day for 20 days)
Study: 2438613
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by radiotherapy (20 Gy IF)
Study: 2438613
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by chemotherapy (1 X COPP/ABVD)
Study: 2473363
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 X CEVD in case of persisting disseminated disease)
Study: 29856832
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity and body composition
Study: 28452705
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution nasal-pharyngeal irrigation (NSNPI) for 30 days
Study: 28452705
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FPNS) for 30 days
Study: 24646362
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 400 mg, 600 mg, and 800 mg (combined)
Study: 24646362
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (all doses combined)
Study: 19004596
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture as an adjunct to methadone detoxification
Study: 19004596
Drug: Standard methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methadone detoxification treatment (Control)
Study: 17531569
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high hs‐CRP levels (>7.5 mg/L)
Study: 17531569
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low hs‐CRP levels (<=1 mg/L)
Study: 11729476
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (M-VAC: methotrexate, vinblastine, adriamycin, cisplatin)
Study: 8683846
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A capsules given to 42 children
Study: 7044607
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (coronary bypass surgery)
Study: 7000170
Drug: Acyclovir 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 2% ointment 5 times a day
Study: 7000170
Drug: Idoxuridine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxuridine 1% ointment 5 times a day
Study: 28814158
Drug: oxymorphone patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxymorphone patches + capsaicin
Study: 28814158
Drug: oxymorphone patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxymorphone patches - capsaicin
Study: 25885807
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups offered nicotine replacement therapy if feasible
Study: 16468059
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CV with other parameters
Study: 14649401
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment maintained
Study: 14649401
Drug: Warfarin stopped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin stopped prior to surgery
Study: 11030374
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenges with cow's milk, hen's egg, wheat, and soy
Study: 11030374
Drug: Parenteral medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral medication
Study: 11030374
Drug: Establishing intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Establishing intravenous access
Study: 7812205
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq daily for a median of 5.7 months
Study: 7812205
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq weekly
Study: 7812205
Drug: Third induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third induction treatment with human lymphoblastoid IFN alpha-n1
Study: 3287839
Drug: 1-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week treatment with pivampicillin plus pivmecillinam
Study: 3287839
Drug: 3-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-week treatment with pivampicillin plus pivmecillinam
Study: 27902522
Drug: Hydroquinone cream
Normalized name: Hydroquinone Cream
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone cream
Study: 26601555
Drug: Propofol (0.2-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.2-0.5 mg/kg)
Study: 21480412
Drug: Saffron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (100 mg daily for 6 weeks)
Study: 16547654
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with beta blockers
Study: 16547654
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III antiarrhythmic agents (sotalol and amiodarone)
Study: 14535873
Drug: Esomeprazole 2
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg